Management of superficial basal cell carcinoma: Focus on imiquimod

Clinical, Cosmetic and Investigational Dermatology

Volumn 2, Issue , 2009, Pages 65-75

  Raasch, Beverly ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Imiquimod; Skin cancer; Superficial basal cell carcinoma

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; FLUOROURACIL; IMIQUIMOD; PLACEBO;

ACTINIC KERATOSIS; APPLICATION SITE BURNING; APPLICATION SITE DISCHARGE; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE ULCER; BASAL CELL CARCINOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CAUTERIZATION; CHEMOSURGERY; CLINICAL FEATURE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; CREAM; CRYOSURGERY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG WITHDRAWAL; EROSION; FOLLOW UP; HUMAN; INNATE IMMUNITY; MORBIDITY; PHOTODYNAMIC THERAPY; REVIEW; SKIN INDURATION; SUPERFICIAL CANCER; TREATMENT RESPONSE;

EID: 77953398182     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: 10.2147/ccid.s3507     Document Type: Review

References (76)

1. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327:794.
2. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;159:35-48.
3. Heenan PJ, Elder DJ, Sobin LH. Histological typing of skin tumours. 26 In: WHO International Histological Classification of skin tumours, 2nd edn. Berlin: Springer Verlag. 1996;48-51.
4. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol. 2006; 155:401-407.
5. Bastiens MT, Hoefnagel JJ, Bruin JA, et al. Differences in age, site distribution and sex between nodular and superficial basal cell carcinomas indicate different types of tumours. Jnl Invest Dermatol. 1998;110:880-884.
6. DeLauney W, Land W, Rotstein H. Principles and Practice of Dermatology 3rd Edition. Sydney Butterworth Heinemann. 1993.
7. Griffiths RW. Audit of histologically incompletely excised basal cell carcinomas: recommendations for management by re-excision. Br J Plast Surg. 1999;52:24-28.
8. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, et al. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007;157(Suppl 2):47-51.
9. Jiang SB, Szyfelbein K. Pathology: Basal Cell Carcinoma. In Emedicine, Nawaz S, Talavera F, Sherif M, Slack CL, Meyers AD Editors. Accessed 24 November 2008. http://www.emedicine.com/ent/TOPIC672.HTM.
10. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Intervntions for basal cell carcinoma of the skin. Cochrane database Syst Rev: CD003412. Review. 2007.
11. Cancer Council Australia and Australian Cancer Network, Basal cell carcinoma, squamous cell carcinoma (and related lesions)-guide to clinical management in Australia. Sydney. 2008.
12. Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol. 1990;23(6 Pt 1):1118-1126.
13. Nagore Em Grau C, Molinero J, Fortea JM. Positive margins in basal cell carcinoma:relationship to clilnical features and recurrence risk. A retrospective study of 248 patients. J Eur Acad Dermatol Venereol. 2003;17(2):167-170.
14. Walker P, Hill D. Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol. 2006;47:1-12.
15. Raasch B, Woolley T. Management of primary superficial basal cell carcinoma. Aust Fam Physician. 2006;36(6):455-458.
16. Cielley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinomas. Int J Dermato. 2006;45: 489-498.
17. Wu JK, Oh C, Strutton G, Siller G. An open label pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular BCC. Australas J Dermatol. 2006;47:46-48.
18. Soler AM, Warloe T, Berner A, Giercksky KE. A follow up study of recurrence andn cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-amino laevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol. 2001;145:467-471.
19. Thissen MT, Neumann MH, Schouten LJ. A systematice review of treatment modalities for primary basal cell carcinomas. Arch Dermatol. 1999;135(10):1177-1183.
20. Kokoszka A Scheinfield N. Evidence - based review of the use of cryosurgery in treatment of basal cell carcinoma. Dermatol Surg. 2003;29:566-571.
21. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15(3):315-328.
22. Graham G. Cryosurgery. Clin Plast Surg. 1993;20:131-147.
23. Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Prac Oncolo. 2007;4:462-469.
24. Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997;76:100-106.
25. Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision vs Mohs micrographic surgery for basal cell carcinoma of the face: randomized controlled trial. Lancet. 2004;364(9447):1766-1772.
26. Rhodes LE, de Rie M, Enström Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma:results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17-23.
27. Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P. Treatment of basal-cell carcinoma:comparison of radiotherapy and cryotherapy. Clin Radiol. 1986;37:33-34.
28. Thissen MR, Nieman FH, Ideler AH, Berretty PJ, Neumann HA. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg. 2000;26(8):759-764.
29. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs cryosurgery of basal cell carcinomas:results of a phase III clinical trial. Br J Dermatol. 2001;144(4):832-840.
30. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18(5):547-53. Epub 2008 Aug 8.
31. Haller JC, Cairnduff F, Slack G, et al. Routine double treatments of superficial basal cell carcinoma using aminolaevulinic acid-base photodynamic therapy. Br J Dermatol. 2000;143:1270-1275.
32. Miller BH, Shavin JS, Cognetta A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil or epinephrine injectable gel J Am Acad Dermatol. 1997;36(1):72-77.
33. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs topical 5-fluorouracil vs cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157 Suppl 2:34-40.
34. Berman B, Sullivan T, De Araujo T, et al. Expression of FAS receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle Br J Dermatol. 2003;149(Suppl 66):59-61.
35. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939-947.
36. Tyring S, Conant M, Marini M, van der Meijden W, Was K. Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol. 2002;41:810-816.
37. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27:571-577.
38. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol. 2003;149(Suppl 66):57-58.
39. Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol. 2007;157:s2;8-13.
40. Panelli MC, Stashower ME, Slade H, et al. Genome Biology. 2007;8:R8.
41. Clark RA, Huang S, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulaion of vascular E-selectin and recruitment of regulatory T cells. J Exp Med. 2008;205(10):2221-2234.
42. Hanger C, Dalrymple J, Hepburn D. Systemic side effects from topical imiquimod. N Z Med J. 2005;118(1223):U1682.
43. Wagstaff AJ, Perry CM. Topical Imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs. 2007;67(15):2187-2210.
44. Goldgeier M, Foz CA, Zavislan JM, Harris D, Gonzalez S. Noninvasive imaging, treatment and microscopic confirmation of clearance of basal cell carcinoma. Dermatol Surg. 2003;29(3):205-210.
45. Astner S, Dietterle S, Otberg N, Roewert-Huber HJ, Stockfleth E, Lademann J. Clinical applicability of in vivo fluorescence confocal microscopy for noninvasive diagnosis and therapeutic monitoring of nonmelanoma skin cancer. J Biomed Opt. 2008;13(1):014003.
46. Geisse JK, Rich P, Pandaya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized vehicle-controlled study. J Am Acad Dermatol. 2002;47:390-398.
47. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III randomized vehicle controlled studies. J Am Acad Dermatol. 2004;50(5):722-733.
48. Physician's Desk reference. 2006;1815.
49. Australian Government Department of Health and Ageing. July 2006 PBAC outcomes: positive recommendations. Accessed 22 August 2006. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ pbacrec-pbacrecjul06-positive imiquimod. 2006.
50. Cancer Research UK. http://www.cancerhelp.org.uk/help/default. asp?page = 11892 Last accessed 25 November 2008 Last updated 11 November 2008.
51. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41(6):1002-1007.
52. Marks R, Gebauer K, Schumack S, et al; Australasian Multicentre Trial Group. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma; results of a multicenter 6 week dose-response trial. J Am Acad Dermatol. 2001;44:807-813.
53. Sterry W, Ruzicka T, Herrara E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147:1227-1236.
54. SINS study http://www.nottingham.ac.uk/dermatology/sins.htm. Last accessed 25 November. 2008.
55. Gollnick H, Barona CG, Frank RGJ, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with iquimod 5% cream: interim 2 year results from an ongoing 5 year follow-up study in Europe. Eur J Dermatol. 2005;15(5):374-381.
56. Quirk C, Gebauer K, Owens M, Stampone P. Two year interim results from a 5 year study evaluationg clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol. 2006;47:258-265.
57. Murphy ME, Brodland DG, Zitelli JA. Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy. Dermatol Surg. 2008;34:1-6.
58. Mendonça CO, Yates VM. Permanent facial hypopigmentation following treatment with imiquimod cream. Clin Exp Dermatol. 2006;31(5):721-722.
59. Vanaclocha F, Daudén E, Badía X, et al. Cost effectiveness of treatment of superficial basal cell carcinoma: surgical excision vs imiquimod 5% cream. Br J Dermatol. 2007;156(4):769-771.
60. Ezughah FI, Dawe RS, Ibbotson SH, Fleming CJ. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. J Dermatol Treat. 2008;19:111-117.
61. Bukhardt Pérez MP, Ruiz-Villaverde R, Naranjo Díaz MJ, Blasco Melguizo J, Naranjo Sintes R. Basal cell carcinoma: treatment with imiquimod. Int J Dermatol. 2007;46:539-542.
62. Berman B. Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinoma. J Drugs Dermatol. 2008;7(1 Suppl 1): s3-s6.
63. Rigel DS, Torres AM, Ely H. Imiquimod 5% cream following curettage without electrodessication for basal cell carcinoma: preliminary report. J Drugs Dermatol. 2008;7(1 Suppl 1):s15-s16.
64. Tillman DK Jr, Carroll MT. A 36 month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drug Dermatol. 2008;7(1Suppl1): s7-s14.
65. Thissen MR, Kuijpers D, Krekels GA. Local immune modulator (imiqumod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. J Drugs Dermatol. 2006;5(5):461-464.
66. Gollnick H, Barona CG, Frank RGJ, et al. Eur J Dermatol. 2008;18(6):677-682.
67. Vidal D, Matias-Guiu X, Alomar A. Fifty five basal cell carciomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol. 2007;143:266-268.
68. Drehs MM, Cook-Bolden F, Tanzi EL, Weinerg JM. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: Case report and review of the literature. Dermatol Surg. 2002;28(5):427-429.
69. Chen TM, Rosen T, Orengo I. Treatment of a large superficial basal cell carcinoma with 5% imiquimod: case report and review of the literature. Dermatol Surg. 2002;28:344-346.
70. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg. 2000;26:577-578.
71. Micali G, Lacarrubba F, Nasca MR, De Pasquale R. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlins syndrome. Clin ExpDermatol. 2003;28(Suppl 1): 19-23.
72. Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol. 2005;141(8): 985-993.
73. Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs. 2007;67(15):2187-2210.
74. Kuijpers DI, Thissen MR, Berretty PJ, Ideler FH, Nelemans PJ, Neumann MH. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma Dermatol Surg. 2007;33(5):579-587
75. Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P. Treatment of basal-cell carcinoma:comparison of radiotherapy and cryotherapy. Clin Radiol. 1986;37:33-34.
76. Lee S, Selva D, Huilgol S, Goldberg RA, Leibovitch I. Pharmacological treatments for basal cell carcinoma. Drugs. 2007;67(6):915-934.